These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Superhigh-dosage chemotherapy with the transplantation of autologous hemopoietic precursor cells in patients with a prognostically unfavorable relapse and resistant course of lymphogranulomatosis].
    Author: Ptuskin VV, Uss AL, Demina EA, Chervonobab IuV, Milanovich NF, Tupitsyn NN, Larionova VB, Batan ZE, Kondrat'eva NE, Zmachinskiĭ VA, Andreeva LA, Snegir' VM, Mkheidze DM, Chimishkian KL.
    Journal: Ter Arkh; 1997; 69(10):49-55. PubMed ID: 9471790.
    Abstract:
    Eighteen patients with relapsed or refractory Hodgkin's disease (HD) have been treated with high-dose chemotherapy (BEAM regimen) followed by autologous peripheral stem cells and/or bone marrow rescue. There were no treatment-related deaths. Overall response rate was 82%. With a median follow-up of 10 months (3-24 months) overall survival and freedom from progression were 100 and 94% (95% confidence interval 58-97%), respectively. The use of peripheral stem cells in addition to bone marrow resulted in a significant shortening of the time to engraftment (p < 0.01). The BEAM regimen is an effective conditioning schedule which is well tolerated.
    [Abstract] [Full Text] [Related] [New Search]